Catalyst Pharmaceutical CPRX Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Product | |||||
| Agamree | $117.09M+154% | $46.04M— | —— | —— | |
| Firdapse | $358.38M+17.1% | $306.04M+18.4% | $258.43M+20.8% | $213.94M+55.0% | |
| Fycompa | $113.34M-17.4% | $137.25M-0.6% | $138.08M— | $0— | |
| Product Revenue Net | $588.81M+20.3% | $489.33M+23.4% | $396.5M+85.3% | $213.94M+55.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Catalyst Pharmaceutical break its business down?
- Catalyst Pharmaceutical (CPRX) reports revenue by product across 4 parts — Agamree, Firdapse, Fycompa and Product Revenue Net. Each is extracted from the segment footnotes and tracked over time.
- Where does Catalyst Pharmaceutical's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Catalyst Pharmaceutical's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
